focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,023.50
Bid: 1,024.50
Ask: 1,025.00
Change: -1.50 (-0.15%)
Spread: 0.50 (0.049%)
Open: 1,023.50
High: 1,027.50
Low: 1,019.50
Prev. Close: 1,025.00
SN. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Retirement of Chief Executive Officer by end 2018

9 Oct 2017 07:00

RNS Number : 0016T
Smith & Nephew Plc
09 October 2017
 

 

 

Notice of Chief Executive Officer's intention to retire by end of 2018

 

9 October 2017

 

Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, announces today that Olivier Bohuon, 58, has notified the Board of his intention to retire by the end of 2018, after seven years as Chief Executive Officer. The Board is commencing a search for a successor. In the meantime, Olivier will continue to lead Smith & Nephew and drive the Company's growth initiatives and operating plans.

 

Olivier Bohuon, CEO said:

"Since I joined the Company in 2011, we have transformed Smith & Nephew into a more focused, efficient and innovative business and I am proud of the value we have created for all of our stakeholders. Looking ahead to the next long-term phase of growth, I have decided to announce my retirement plans now, providing ample time to identify a successor and ensure a smooth transition. I am committed to leading the Company in the meantime, as we remain resolutely focused on delivering a solid performance in 2017, while positioning the Company for further success in the future."

 

Roberto Quarta, Chairman said:

"On behalf of the Board, I want to thank Olivier for his professional and personal commitment and dedication to Smith & Nephew during his tenure as our CEO. Under Olivier's leadership Smith & Nephew has undergone important and necessary change and is now a stronger Company. As Smith & Nephew enters its next chapter, the Board is determined to build on this to deliver accelerating growth, improved efficiency and further value for shareholders."

 

This announcement contains inside information.

 

Ends

 

Enquiries

 

Investors

Ingeborg Øie

+44 (0) 20 7960 2285

Smith & Nephew

Media

Charles Reynolds

+44 (0) 1923 477314

Smith & Nephew

Ben Atwell / Debbie Scott

+44 (0) 20 3727 1000

FTI Consulting

 

Forward calendar

The Q3 Trading Report will be released on 3 November 2017.

 

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were almost $4.7 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

 

For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGMMGGGRLGNZZ
Date   Source Headline
6th Jul 20237:00 amRNSNotice of Results
3rd Jul 20234:07 pmRNSTotal Voting Rights
30th Jun 202310:21 amRNSDirector Declaration
1st Jun 202312:30 pmRNSTotal Voting Rights
24th May 20234:45 pmRNSDirector/PDMR Shareholding
19th May 20234:15 pmRNSDirector/PDMR Shareholding
5th May 20237:08 amRNSDividend Declaration
5th May 20237:00 amRNSDirector Declaration
3rd May 20239:30 amRNSDirector/PDMR Shareholding
2nd May 20231:53 pmRNSTotal Voting Rights
27th Apr 20233:25 pmRNSDirector/PDMR Shareholding
26th Apr 20233:36 pmRNSResult of AGM
26th Apr 20237:00 amRNSQ1 2023 Trading Update
6th Apr 20237:00 amRNSNotice of First Quarter 2023 Trading Report
3rd Apr 20232:07 pmRNSTotal Voting Rights
13th Mar 20231:45 pmRNSDirector/PDMR Shareholding
6th Mar 20236:00 pmRNSAnnual Financial Report
1st Mar 20232:44 pmRNSTotal Voting Rights
22nd Feb 20231:07 pmRNSDirector/PDMR Shareholding
21st Feb 20231:41 pmRNSDirector/PDMR Shareholding
21st Feb 20237:00 amRNSFinal Results
17th Feb 20237:00 amRNSDirectorate Change
1st Feb 20234:15 pmRNSBlock listing Interim Review
1st Feb 202311:20 amRNSTotal Voting Rights
26th Jan 202312:22 pmRNSNotice of Results
19th Jan 20233:19 pmRNSDirector/PDMR Shareholding
3rd Jan 20231:47 pmRNSTotal Voting Rights
12th Dec 20224:37 pmRNSDirector/PDMR Shareholding
9th Dec 202211:30 amRNSDirector/PDMR Shareholding
1st Dec 20222:00 pmRNSTotal Voting Rights
16th Nov 202211:30 amRNSDirector/PDMR Shareholding
10th Nov 20227:00 amRNSDirector/PDMR Shareholding
3rd Nov 20227:00 amRNS3rd Quarter 2022 Trading Report
1st Nov 202210:38 amRNSTotal Voting Rights
28th Oct 202211:45 amRNSDirector/PDMR Shareholding
14th Oct 20227:01 amRNSDividend Declaration
14th Oct 20227:00 amRNSTiming of Smith & Nephew Q3 2022 Trading Update
5th Oct 20227:00 amRNSEuro Bond Issue
3rd Oct 202212:53 pmRNSTotal Voting Rights
14th Sep 20223:00 pmRNSDirector/PDMR Shareholding
1st Sep 20221:33 pmRNSTotal Voting Rights
1st Sep 20227:00 amRNSBoard Committee Membership
23rd Aug 20225:05 pmRNSDirector/PDMR Shareholding
23rd Aug 20224:25 pmRNSDirector/PDMR Shareholding
16th Aug 20224:57 pmRNSDirector/PDMR Shareholding
12th Aug 20225:40 pmRNSTransaction in Own Shares
12th Aug 20224:45 pmRNSDirector/PDMR Shareholding
11th Aug 20226:21 pmRNSTransaction in Own Shares
10th Aug 20226:06 pmRNSTransaction in Own Shares
9th Aug 20226:16 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.